Proteins have the most diverse and dynamic role among all macromolecules in the body, providing intracellular and extracellular scaffold support, forming receptors and channels in membranes, catalyzing biochemical reactions, and transporting molecules within the cell.
Protein therapeutics have several advantages over small molecule drugs. First, proteins usually have highly specific and complex functions that cannot be mimicked by simple chemical compounds. Second, there is often less potential for protein therapeutics to interfere with normal biological processes and cause adverse reactions, as the action of proteins is highly specific. Third, since the body naturally produces many proteins as therapeutics, these agents are generally well tolerated and are unlikely to elicit immune responses. Fourth, for diseases caused by gene mutations or deletions, protein therapeutics can provide effective alternative treatments without the need for gene therapy.
The in vivo disposition of protein drugs can be predicted to a large extent from their physiological function. The short elimination half-life can be expected from small proteins with hormone activity, which is ideal for close regulation of endogenous levels and functions. In contrast, proteins with transport function and long-term immune function can usually be observed with a longer half-life of several days to ensure the continuous maintenance of physiologically necessary concentrations in systemic circulation. Similar to small molecule compounds, the pharmacokinetic process of protein drugs generally includes absorption, distribution, and elimination. However, the special processing of protein drugs may involve target receptor-mediated drug disposition, and interactions with Fc receptors. These two pathways play major roles in the pharmacokinetics of monoclonal antibodies.
At Creative Bioarray, we understand that getting access to the right protein is a major obstacle to successful downstream research applications in the drug discovery process. Over the past 10 years, we have continuously invested and expanded our expert team, technology platform, capabilities and service scope to one of the most advanced research protein service team in the drug discovery industry.
Efficacy assays are the basis for understanding your therapeutics' activity in order to provide information for development program.
Creative Bioarray can perform both efficacy and safety assays allowing for early, cost-effective assessments. Binding assays, such as ELISA, can be performed to verify target binding, especially useful following protein engineering, and we can go further with in vitro activity assays.
Creative Bioarray can help you advance your project, contact us now to discuss further with our accessible and specialized team.